GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Cyclically Adjusted PS Ratio

Evolutionary Genomics (Evolutionary Genomics) Cyclically Adjusted PS Ratio : (As of Jun. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evolutionary Genomics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Evolutionary Genomics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolutionary Genomics Cyclically Adjusted PS Ratio Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.83 1.50 - -

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evolutionary Genomics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Evolutionary Genomics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolutionary Genomics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's Cyclically Adjusted PS Ratio falls into.



Evolutionary Genomics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Evolutionary Genomics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2022 is calculated as:

For example, Evolutionary Genomics's adjusted Revenue per Share data for the three months ended in Dec. 2022 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=0/125.2218*125.2218
=0.000

Current CPI (Dec. 2022) = 125.2218.

Evolutionary Genomics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 2.677 99.070 3.384
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.014 100.392 0.017
201512 0.035 99.792 0.044
201603 0.012 100.470 0.015
201606 0.009 101.688 0.011
201609 0.005 101.861 0.006
201612 0.012 101.863 0.015
201703 0.005 102.862 0.006
201706 0.001 103.349 0.001
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.013 106.507 0.015
201812 0.006 105.998 0.007
201903 0.005 107.251 0.006
201906 0.009 108.070 0.010
201909 0.006 108.329 0.007
201912 0.001 108.420 0.001
202003 0.002 108.902 0.002
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.002 109.897 0.002
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evolutionary Genomics  (OTCPK:FNAM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Evolutionary Genomics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolutionary Genomics (Evolutionary Genomics) Business Description

Traded in Other Exchanges
N/A
Address
4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
Executives
Steve B Warnecke director, 10 percent owner, officer: Chairman, CEO C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff director 4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier officer: Secretary / Treasurer 1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess director 7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz director, 10 percent owner 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess director, 10 percent owner, officer: President/CEO 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita director, officer: Secretary/Treasurer/CFO 5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines